Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Pliant Therapeutics (PLRX) over the last 7 years, with Q3 2025 value amounting to $6.4 million.

  • Pliant Therapeutics' Share-based Compensation fell 2787.95% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year decrease of 2146.71%. This contributed to the annual value of $37.6 million for FY2024, which is 1541.49% down from last year.
  • According to the latest figures from Q3 2025, Pliant Therapeutics' Share-based Compensation is $6.4 million, which was down 2787.95% from $6.4 million recorded in Q2 2025.
  • Pliant Therapeutics' 5-year Share-based Compensation high stood at $13.0 million for Q2 2023, and its period low was $2.3 million during Q2 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $8.4 million (2024), whereas its average is $7.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 50658.82% in 2021, then tumbled by 4007.89% in 2025.
  • Quarter analysis of 5 years shows Pliant Therapeutics' Share-based Compensation stood at $2.8 million in 2021, then soared by 292.16% to $10.9 million in 2022, then decreased by 15.69% to $9.2 million in 2023, then fell by 8.03% to $8.4 million in 2024, then dropped by 23.75% to $6.4 million in 2025.
  • Its Share-based Compensation stands at $6.4 million for Q3 2025, versus $6.4 million for Q2 2025 and $8.9 million for Q1 2025.